Gilder Gagnon Howe & Co. LLC Purchases 58,920 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Gilder Gagnon Howe & Co. LLC grew its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 6.7% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 931,894 shares of the medical device company's stock after buying an additional 58,920 shares during the period. Gilder Gagnon Howe & Co. LLC owned approximately 1.42% of Tandem Diabetes Care worth $33,567,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. AlphaQuest LLC grew its position in shares of Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after buying an additional 541 shares during the period. Jones Financial Companies Lllp raised its stake in shares of Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after purchasing an additional 748 shares in the last quarter. Assetmark Inc. increased its position in Tandem Diabetes Care by 77.5% during the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after buying an additional 535 shares during the last quarter. McIlrath & Eck LLC acquired a new position in shares of Tandem Diabetes Care in the third quarter valued at approximately $52,000. Finally, Smartleaf Asset Management LLC grew its position in shares of Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock worth $65,000 after purchasing an additional 1,101 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Mizuho began coverage on shares of Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price objective for the company. Piper Sandler reduced their price objective on shares of Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating for the company in a research report on Thursday. Wells Fargo & Company decreased their target price on Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating for the company in a research report on Thursday. Robert W. Baird lowered their price target on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating on the stock in a report on Thursday. Finally, Barclays cut their target price on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $40.06.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ:TNDM traded up $3.14 during midday trading on Thursday, hitting $19.99. The stock had a trading volume of 2,480,916 shares, compared to its average volume of 1,511,058. The stock has a 50 day moving average price of $19.30 and a two-hundred day moving average price of $28.87. The company has a market capitalization of $1.33 billion, a PE ratio of -10.34 and a beta of 1.52. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 1 year low of $15.75 and a 1 year high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The firm had revenue of $234.42 million for the quarter, compared to analyst estimates of $220.19 million. During the same quarter last year, the business posted ($0.65) EPS. The firm's revenue was up 22.3% compared to the same quarter last year. As a group, equities analysts predict that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Insider Activity at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos purchased 10,538 shares of Tandem Diabetes Care stock in a transaction dated Friday, March 7th. The stock was bought at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the acquisition, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.90% of the stock is currently owned by company insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.